Ireland's Shire AG may be acquired by Takeda Pharmaceutical for £ 46 billion

Shire is a global leader in pharmaceuticals for rare diseases, with a global turnover of 11.4 billion USD in 2016. The move is hotly debated in Japan, giving voice to Takeda becoming an international group with a reduced Japanese footprint. Other arguments are that the number of Japanese ventures iand the amount of invested funds increases, and the Japanese bio industry may be in a serious shortage of human resources.

Source: Nikkei Biotech news release, May 8, 2018

Request a quote for deeper information from
contact@asia-tech.eu

© 2018 Window to Japan - Bio 4 Business - Imprint